openPR Logo
Press release

Global Glaucoma Therapeutics Market: Value Growth over Forecast Period Attributed to Strong Pipeline of Combination Drugs, predicts TMR

02-02-2017 09:56 PM CET | Health & Medicine

Press release from: Transparency Market Research - Pharmaceutical

Global Glaucoma Therapeutics Market: Value Growth over

The global glaucoma therapeutics market is immensely consolidated and the top five players accounted for just under 85.0% of the market in 2015. Among Novartis AG, Allergan plc., Pfizer Inc., Merck & Co., and Santen Pharmaceuticals, Novartis is the clear leader with a massive share of over 33.0%.

Transparency Market Research has observed that most companies have a hold over the market owing to their well-established brands and a strong pipeline of drugs for the treatment of glaucoma. However, loss in the market share of leading companies due to patent expiry is likely to offset the competitive landscape in the coming years.

The global glaucoma therapeutics market is projected to rise from a value of US$5.7 bn in 2015 to US$7.6 bn by 2024 at a modest CAGR of 3.4% therein.

North America Dominates Global Market by Revenue

Based on drug class, the glaucoma therapeutics market is led by the combination segment, which is projected to account for a share of 25.8% by 2024. Expanding at an 8.8% CAGR from 2016 to 2024, the segment is fueled by the cost-effective nature of these drugs as compared to individual drugs. On the basis of end use, hospitals formed the leading segment of the glaucoma therapeutics market in 2015. The maximum opportunity was also presented by this segment. Hospitals provide healthcare services at an affordable cost to citizens across the U.S., Canada, the U.K., and several other countries in Europe. This has ensured the dominance of the hospitals segment.

Browse Global Strategic Business Report:
http://www.transparencymarketresearch.com/glaucoma-therapeutics-market.html

Geographically, North America is expected to account for a large share in the glaucoma therapeutics market in terms of revenue owing to the rising usage of highly priced prostaglandins. The region accounted for almost half the market in 2015. Exhibiting a 4.2% CAGR from 2016 to 2024, Asia Pacific presents immense scope for growth. India holds a major share in the APAC market in terms of revenue owing to the rising prevalence of glaucoma in the country and a comparatively lower cost of treatment.

Improving Socio-economic Living Conditions Key in Driving Uptake of Glaucoma Therapeutics

The growing need to offer improved eye care and preserve the vision of the patients among healthcare providers has resulted in the development of enhanced therapeutic options for the treatment of glaucoma. “Although eye drops have, until recent years, been the primary method of treatment, the market has been witnessing an evident shift toward combination drugs,” the author notes. The strong pipeline of combination drugs for the treatment of glaucoma therefore ensures steady growth of this market. Aerie Pharmaceuticals’ pipeline of combination drugs such as Rho Kinase Inhibitor (ROCKi) and norepinephrine transport inhibitor (NETi) is a key example of this development.

In addition to this, an improvement in the socio-economic conditions of people in developing countries has increased spending capacity, which has not only resulted in a rise in healthcare expenditure but also led a surge in awareness about living a healthy lifestyle. This has, in turn, upped the early detection of glaucoma and spurred the demand for glaucoma therapeutics.

In contrast, the possible side effects of glaucoma drugs and the growth of the generic drugs market are likely to be the key deterrents in the coming years.

This review is based on the findings of a TMR report titled “Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024.”

Glaucoma Therapeutics Market, by Drug Class

Alpha Agonist
Beta Blockers
Prostaglandin Analogs
Carbonic Anhydrase Inhibitor
Cholinergic
Combined Medication
Glaucoma Therapeutics Market, by End Users

Ophthalmic clinic
Hospitals
Ambulatory Surgical Centers
Glaucoma Therapeutics Market, by Geography

North America
U.S.
Canada
Latin America
Brazil
Mexico
Rest of Latin America
Europe
U.K.
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
India
Japan
China
Australia
New Zealand
Rest of Asia Pacific
Middle East and Africa
South Africa
Saudi Arabia
U.A.E.
Rest of MEA

Download Exclusive Brochure of This Report :
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16406

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Glaucoma Therapeutics Market: Value Growth over Forecast Period Attributed to Strong Pipeline of Combination Drugs, predicts TMR here

News-ID: 427637 • Views:

More Releases from Transparency Market Research - Pharmaceutical

Neurovascular Devices Market Business Opportunities and Growth Challenges Report
Neurovascular Devices Market Business Opportunities and Growth Challenges Report
Global Neurovascular Devices Market: Overview The global population is aging rapidly. According to WHO, the chances of health risks are greater in geriatric people than the young generation. Old age is considered to be one of the biggest risk factors that are responsible for developing various diseases such as cardiovascular and neurological conditions. It is because of these factors, the global neurovascular devices market is experiencing robust growth in the
Pneumococcal Vaccines Market anticipated expand at a CAGR of 3.3% from 2018 to 2026
Pneumococcal Vaccines Market anticipated expand at a CAGR of 3.3% from 2018 to 2 …
Transparency Market Research (TMR) has published a new report titled, “Pneumococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global pneumococcal vaccines market was valued at US$ 7,247.6 Mn in 2017 and is anticipated expand at a CAGR of 3.3% from 2018 to 2026. Increase in patient pool, growth of the pharmaceutical industry, government initiatives to increase vaccination programs, rise
Swab and Viral Transport Medium Market projected to expand at a CAGR of ~3% from 2020 to 2030
Swab and Viral Transport Medium Market projected to expand at a CAGR of ~3% from …
Swab and Viral Transport Medium Market: Introduction Transparency Market Research has published a new report titled, ‘Global Swab and Viral Transport Medium Market ’. According to the report, the global swab and viral transport medium market was valued at US$ 0.9 Bn in 2019 and is projected to expand at a CAGR of ~3% from 2020 to 2030. Viral transport medium (VTM) enables safe transfer of viruses, chlamydia, and mycoplasma for
Radiofrequency Ablation Devices Market by Product, Geography and Forecast to 202 …
Transparency Market Research (TMR) has published a new report titled, 'Radiofrequency Ablation Devices for Pain Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027'. According to the report, the global radiofrequency ablation devices for pain management market was valued at US$ 543.0 Mn in 2018 and is projected to expand at a CAGR of above 11.0% from 2019 to 2027. Overview Radiofrequency ablation is a minimally invasive surgical

All 5 Releases


More Releases for Glaucoma

Micro-Invasive Glaucoma Implants Micro-Invasive Glaucoma Implants
Global Micro-Invasive Glaucoma Implants Market Definition: Micro-invasive glaucoma implants is performed for the treatment of the open- angle glaucoma and is done through an ab- interno approach. It is very safe and provides faster recovery as compared to the traditional methods. They usually lower the intraocular by increasing the flow or reducing the production of the aqueous humor. Increasing cases of the glaucoma worldwide is the major factor fueling the
Glaucoma – Epidemiology Insights (2016-2028)
Glaucoma can be described as a group of diseases characterized by cupping of the optic nerve head and visual-field damage. These diseases differ from each other in terms of their causes, risk factors, demographics, symptoms, duration, treatment, and prognosis. Download the sample report @ https://www.pharmaproff.com/request-sample/1159 The common identifiable features for all forms of glaucoma are loss of retinal ganglion cells, thinning of the retinal nerve fiber layer, and cupping of the
Market Spotlight: Glaucoma
Boston, MA ReportsWorldwide has announced the addition of a new report title Market Spotlight: Glaucoma to its growing collection of premium market research reports. Glaucoma is not just one eye disease, but a group of eye conditions resulting in optic nerve damage, which may cause loss of vision and blindness. In glaucoma, damage to the optic nerve is usually caused by elevated intraocular pressure (IOP). IOP rises when passages that allow fluid
North America Glaucoma Therapeutics Market grows with growing awareness regardin …
Glaucoma Therapeutics Market: Scope and Methodology The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major glaucoma therapeutics market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study
Glaucoma Treatment Market : Rising Geriatric Population And Healthcare Expenditu …
Glaucoma is a chronic, degenerative, permanent disorder whose rate increases essentially with age rather than causing immediate blindness. According to a survey of WHO, Glaucoma is the second most common cause of blindness affecting the population worldwide after cataract (47.9%). In general, Glaucoma occurs as after effects of increased intraocular pressure (IOP) brought about by an abnormality or malfunctioning of the eye drainage system. The normal IOP is in
Glaucoma Surgery Devices Market 2016: Glaucoma Systems, Glaucoma Laser Devices
Latest industry research report on Glaucoma surgery devices are used in the glaucoma treating procedure. These procedures include both surgical and laser therapies performed on a patient. The cases of blindness due to glaucoma is on rise across the several countries. Furthermore, the demand for both technologically as well as advanced surgical equipment has resulted in the popularity of glaucoma surgery devices industry, worldwide. Sudden increase in the aging population and